JOURNAL OF COMPLEMENTARY MEDICINE RESEARCH
Journal of Complementary Medicine Research, ISSN: 2146-8397 Vol. 14, No. 2, 2023 (pp.179-183)
RESEARCH ARTICLE
WWW.JOCMR.COM

Possibilities of Modern Medicine in the Field of Early Diagnosis of Parkinson's Disease

Medjid O. Nesturov[1], Viktoriia Pavalaki[2], Diana V. Ovsyannikova[3]
Anastasia V. Romanenko[4], Yuriy A. Trusov,[5] Olga A. Malyugina[6]

[1]The Yaroslav-the-Wise Novgorod State University, 173003, Veliky Novgorod, Bolshaya St. Petersburg str., 41
[2]Federal State Budgetary Educational Institution of Higher Education "Orel State University named after I.S.Turgenev", 302026
[3] Saint Petersburg State Pediatric Medical University194100, Saint Petersburg, Litovskaya street, 2
[4]Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Trubetskaya str. Moscow, Russian Federation 119991
[5]Samara State Medical University (89 Chapaevskaya str., Samara, 443099, Russian Federation), cardiologist, Clinics of Samara State MedicalUniversity, 165B Karl Marx str., Samara, 443079, Russian Federation
[6]Tyumen State Medical University, Tyumen, Russian Federation

ABSTRACT

The article examines the possibilities of modern medicine in the field of early diagnosis of Parkinson's disease. As the author points out, the pathogenesis of Parkinson's disease is a complex mechanism that includes many different processes and mechanisms. Understanding these processes and mechanisms can help in the development of new methods of treatment and prevention of PD. Despite the fact that all aspects of the pathogenesis of PD have not been fully studied, there are a number of drugs and technologies that can slow down or reduce the manifestation of PD symptoms.

Corresponding Author e-mail: kos15.00@mail.ru

How to cite this article: Nesturov MO, Pavalaki V, Diana V. Ovsyannikova , Romanenko AV, Yuriy A. Trusov , Malyugina OA.(2023) Possibilities of Modern Medicine in the Field of Early Diagnosis of Parkinson's Disease. Journal of Complementary Medicine Research, Vol. 14, No. 2, 2023 (pp. 179-183)

INTRODUCTION

Parkinson's disease is a neurodegenerative disease that manifests itself by the gradual loss of nerve cells responsible for movement, which leads to decreased coordination and trembling of the limbs. Early diagnosis of Parkinson's disease can be difficult, as symptoms may appear gradually and be implicit in the early stages of the disease.

Diagnosis of Parkinson's disease (PD) is usually based on medical observations and assessment of clinical signs, including the characterization of various motor symptoms. However, traditional diagnostic approaches may suffer from subjectivity, since they are based on the assessment of movements that are sometimes invisible to the human eye and therefore difficult to classify, which leads to possible misclassification. At the same time, early non-motor symptoms of PD can be mild and can be caused by many other conditions. Therefore, these symptoms are often overlooked, which makes it difficult to diagnose PD at an early stage.[1]

There are a number of promising approaches to the diagnosis of Parkinson's disease that can improve the accuracy of diagnosis and early detection of the disease. The development of biomarkers for Parkinson's disease can help in the accurate diagnosis of the disease. Some studies have already shown that certain biomarkers, such as alpha-synuclein protein and neurofilaments, may be associated with the development of Parkinson's disease and can be used for diagnosis.

The use of machine learning and big data analysis can help improve the accuracy of diagnosis of Parkinson's disease. This can allow you to quickly process large amounts of data and find patterns that may indicate the presence of a disease.

Mobile applications that use data from sensors on smartphones can help in the diagnosis of Parkinson's disease. These apps can track movements and changes in speech and help doctors diagnose the disease at an early stage. Genetic analysis can help identify genes that are associated with the risk of developing Parkinson's disease. This may allow early diagnosis of the disease in people at increased risk.

KEYWORDS:
Parkinson's disease,
early diagnosis,
monitoring,
biomarkers,
genetic tests,
imaging,
artificial intelligence.

ARTICLE HISTORY:
Received : Dec 15, 2022
Accepted : Jan 20, 2023
Published: Feb 16, 2023

DOI:
10.5455/jcmr.2023.14.02.28

Artificial intelligence can help in processing medical data and identifying patterns that may indicate the presence of Parkinson's disease. This can help improve diagnostic accuracy and give an earlier diagnosis.[2].

In general, the development of new approaches to the diagnosis of Parkinson's disease gives hope for a more accurate and early diagnosis of the disease, which can improve the effectiveness of treatment and improve the quality of life of patients. However, it should be borne in mind that any new diagnostic method should be tested and confirmed before widespread use in clinical practice. In addition, it is necessary to develop a multidisciplinary approach to the diagnosis of Parkinson's disease, including medical specialists, researchers, engineers and software developers, in order to improve the accuracy of diagnosis and improve the effectiveness of treatment.

MATERIALS AND METHODS

In the process of preparing the work, monographs and articles by a number of domestic and foreign authors were studied, and comparative and analytical research methods were also used in data analysis.

RESULTS

Parkinson's disease (PD) is a neurodegenerative disease characterized by the loss of neurons producing the neurotransmitter dopamine in the area of the brain responsible for coordination of movements and control of muscle tone. This leads to the appearance of motor symptoms, such as trembling, stiffness of movements and gait disorders, as well as other neurological and mental symptoms.

The etiology of PD is not fully understood, but it is believed that the disease can be caused by a combination of genetic and environmental factors. Some genes, including the genes SNCA, LRRK2 and PARK2, are associated with an increased risk of PD. There is also evidence of a link between PD and some environmental factors, such as toxic substances and infections.

The pathogenesis of PD is associated with the formation of neural inclusions called levodoporephyrin corpuscles in dopamine-producing neurons. These corpuscles consist of an aggregated form of the alpha-synuclein protein, which is a key player in the pathology of PD. Under normal conditions, alpha-synuclein participates in the regulation of neurotrans-mission and control of vesicular transport, but in PD it forms aggregates that can lead to disruption of mitochondrial function and generation of free radicals, which, in turn, causes damage to neurons and their subsequent death.[3]

In addition, a violation of the dopaminergic system in the brain and a decrease in dopamine levels caused by the death of neurons leads to a decrease in the activity of the basal ganglia and improper regulation of movements.

In general, the pathogenesis of PD is multidimensional and includes not only neurodegeneration, but also inflammatory processes, an imbalance of metabolicprocesses, as well as mechanisms of apoptosis and autophagy. These processes can interact with each other and form a complex cascade chain leading to the development of PD pathology.[4]

Recently, it has been discovered that other proteins, including albumin glycosylation, amyloid beta and tauprotein, may also participate in the pathogenesis of PD. These proteins can form aggregates that can damage neurons and cause various neuropathological symptoms. Early diagnosis of Parkinson's disease is a difficult task, since the symptoms of the disease may not be obviousin the early stages. However, in recent years, many studies have been conducted aimed at developing methods for early diagnosis of Parkinson's disease. Some of these studies describe the use of clinical methods for the diagnosis of Parkinson's disease. For example, one study showed that a combination of clinical assessments, such as Hoehn and Yahr scores, UPDRS scores and magnetic resonance imaging, can help diagnose Parkinson's disease at an early stage with high accuracy.Other studies describe the use of biomarkers to diagnose Parkinson's disease. For example, some authors indicate that measuring the level of alpha-synuclein protein in the cerebrospinal fluid may be useful for early diagnosis of Parkinson's disease.

Studies have also been conducted using educational machine learning models for the diagnosis of Parkinson's disease. Experts claim that a combination of educational machine learning models and clinical assessments can help diagnose Parkinson's disease with high accuracy. However, despite significant advances in the development of methods for early diagnosis of Parkinson's disease, further research is still needed to improve the accuracy of diagnosis and develop more effective treatments. Diagnosis of Parkinson's disease is a difficult task, since the symptoms of the disease can be very diverse and are not always unique to this disease.[5] In addition, Parkinson's disease can manifest differently in different people, which can make diagnosis difficult. Some of the main challenges of diagnosing Parkinson's disease include:

1. **Inaccuracy of symptoms:** many symptoms of Parkinson's disease, such as trembling, slowness of movement and stiffness, can manifest themselves in other diseases. This can lead to the fact that the diagnosis of Parkinson's disease will be delayed or even incorrect.
2. **Inaccuracy of assessment:** the assessment of the symptoms of Parkinson's disease may be unstable and depend on the experience of the doctor. The same patients may be given different diagnoses, depending on which doctor they turned to.
3. **Inaccuracy of diagnosis at an early stage:** Parkinson's disease at an early stage can be difficult to diagnose due to the lack of characteristic symptoms. This may lead to the diagnosis being made later, when the disease has already advanced.
4. **Limited diagnostic methods:** at the moment there is no specific test for the diagnosis of Parkinson's disease, and the diagnosis is usually made based on the observation of symptoms and the results of various tests, such as MRI, ECG and neuropsychological tests.
5. **Prediction inaccuracy:** predicting the progression of Parkinson's disease is also a difficult task, since its progression can be very diverse and depend on many factors. In general, the diagnosis of Parkinson's disease remains

a challenging task, and research continues to develop new diagnostic methods that can be more accurate and successful.

DISCUSSION

Let's consider the features of modern diagnosis of Parkinson's disease.

The clinical assessment of Parkinson's disease (PD) is based on the observation and assessment of symptoms that are characteristic of this disease. This may include an assessment of motor disorders such as trembling, stiffness and poor movement, as well as non-motor disorders such as depression, apathy and drowsiness.

One of the main tools for the clinical assessment of PD is the Hoech and Yarr scale, which is based on the assessment of the presence and degree of development of symptoms such as trembling, stiffness of movements and akinesia. The Hoech and Yarr scale is used to assess the severity of PD symptoms and determine the effectiveness of treatment.

In addition, neuropsychological testing can be used in the clinical assessment of PD, which allows assessing the patient's cognitive functions, such as attention, memory and thinking. This can help determine the degree of cognitive impairment in the patient and decide whether additional studies, such as brain MRI, are necessary.[6]

Another important tool in the clinical assessment of PD is the assessment of the activity of the patient's daily life. This may include assessing the patient's ability to self-care, ability to move and perform simple tasks.

Recently, the use of sensor devices such as accelerometers and gyroscopes, which allow continuously monitoring the patient's movements and evaluating his functionality, has become increasingly important in the clinical assessment of PD.

In general, the clinical assessment of PD is multidimensional and may include various methods and tools. It allows you to determine the degree of functional impairment in the patient and choose the most effective approach to treatment and rehabilitation.

Neuropsychological tests are used in the assessment of signs of Parkinson's disease (PD) to identify disorders of cognitive functions such as attention, memory, thinking and speech, which often occur in patients with PD. These tests can help determine the degree of cognitive impairment and choose the most effective approach to treatment.

One of the most common neuropsychological tests used in PD is a test for attention and information processing speed. This test measures the patient's ability to respond quickly to changes in external stimuli and switch between tasks.[7]

Another important test is the memory test. It may include reproducing words or images that were presented to the patient earlier. This test measures the patient's ability to remember and store information.

Thinking tests can include logic and abstract thinking tasks. These tests help to determine how well the patient is able to analyze and solve complex problems.

Also, speech and language ability tests can be used to assess the signs of PD. These tests measure the patient's ability to express himself verbally, understand speech and switch between language tasks.

Some neuropsychological tests can also be used to assess a patient's emotional state, such as depression and anxiety tests. These tests can help to identify the presence of concomitant psychological disorders that can worsen the patient's quality of life.[8]

In general, neuropsychological tests are an important tool in assessing the signs of PD. They can help to identify violations of the cognitive and emotional functions of the patient and choose the most effective approach to treatment.

Imaging is a medical technology used to create visual images of internal organs and tissues. It can be used to assess the signs of Parkinson's disease (PD) and help in the diagnosis, treatment and monitoring of its progression. One of the imaging methods used in PD is magnetic resonance imaging (MRI). MRI can help identify changes in the structure of the brain that may indicate the presence of PD, such as a decrease in size or changes in the structure of the substance of the nigra. MRI can also be used to investigate other causes of symptoms that may mimic PD, such as brain tumors.

Another imaging method used in PD is positron emission tomography (PET). PET allows you to measure the activity of glucose metabolism in various parts of the brain. Changes in glucose metabolism may indicate the presence of PD and help in the diagnosis and monitoring of disease progression.

Another imaging method used in PD is single-photon emission computed tomography (SPECT). SPECT can be used to measure the activity of brain neurons and help identify changes associated with PD.[9]

Imaging can also be used to monitor the effectiveness of PD treatment. For example, an MRI scan can help determine how well medications control PD symptoms and how these medications affect changes in brain structure.

In general, imaging is an important tool in assessing the signs of PD. It can help in the diagnosis, monitoring and treatment of the disease, as well as improve understanding of its pathogenesis.

Parkinson's disease (PD) may have a genetic component, and genetic tests can help in the diagnosis, assessment of the risk of developing the disease, as well as in understanding the pathogenesis and choosing the most effective treatment.

One of the genetic tests used in PD is testing for mutations in the SNCA gene. SNCA encodes the protein alpha-synuclein, which is associated with the formation of cellular inclusions characteristic of PD. Mutations in the SNCA gene can lead to an increase in alpha-synuclein levels in the brain and an increased risk of developing PD. Another genetic test used in PD is testing for mutations in the LRRK2 gene. Mutations in the LRRK2 gene can lead to impaired function of brain neurons and an increased risk of PD. Testing for mutations in the LRRK2 gene can be useful for diagnosing and assessing the risk of developing PD.

Genetic tests are also carried out for mutations in the PARK2, PINK1, DJ-1 genes, which are associated with hereditary forms of PD. Mutations in these genes can lead to deterioration of mitochondrial function and damage to brain neurons.

Genetic tests can also help in selecting the optimal treatment. For example, mutations in the LRRK2 gene are associated with increased sensitivity to LRRK2 inhibitors, and patients with such mutations may benefit greatly from this class of drugs.

However, it should be noted that genetic tests are not exhaustive and cannot fully predict the risk of PD. Most cases of PD are multifactorial in nature, and heredity is only one of the risk factors.[10]

In addition, not all PD-related mutations can be detected by genetic tests, and some mutations may be unique to a particular patient or family. Therefore, genetic tests are not mandatory for the diagnosis of PD, and they should be carried out only for medical reasons.

In general, genetic tests can be a useful addition to clinical diagnosis and help in understanding the mechanisms of PD development. However, a broader study of the genetic factors of PD and their interaction with the environment may contribute to the development of new methods for the diagnosis, prevention and treatment of this disease.

Biomarkers are objects that can be measured in biological samples, such as blood, urine, saliva or cerebrospinal fluid, and which may indicate the presence or stage of the disease. In the field of Parkinson's disease (PD), there are many studies on the search and use of biomarkers for diagnosis, assessment of progression and monitoring of treatment effectiveness.

One of the main biomarkers of PD is the protein alpha-synuclein, which forms the main component of pathological protein aggregates (levodopa-induced dyskinesia, Lewy bodies) characteristic of this disease. Analysis of the concentration of alpha-synuclein in the cerebrospinal fluid can be useful for the diagnosis of PD, but this method is invasive and requires a cerebrospinal puncture. A more accessible and less invasive method is to analyze the level of alpha-synuclein in urine, but this technique has low sensitivity and specificity.

Another biomarker of PD is the tau protein, which can also form pathological protein aggregates. However, the level of tau protein in the cerebrospinal fluid and blood does not always correlate with the presence or progression of PD.[11]

Other biomarkers are also being studied, including some metabolites, neurotransmitters and cytokines, which may indicate a violation of metabolic or inflammatory processes in the body of a patient with PD. However, these methods require additional research to establish their effectiveness and applicability in clinical practice.

In general, the use of biomarkers in the diagnosis of PD can significantly improve the accuracy and early diagnosis of this disease. However, there are still no unambiguous and widely used biomarkers, and additional research in this area is needed.

When assessing the signs of Parkinson's disease, symptoms are monitored to establish a diagnosis and track the progression of the disease. One of the main signs of Parkinson's disease is the presence of tremor, which can be distinct at rest or when moving limbs. In addition, patients with Parkinson's disease may have muscle stiffness, slow movements, and problems with balance and coordination.[12]

Monitoring of signs of Parkinson's disease may include an assessment:

1. Tremor. Determination of the type and degree of trembling (at rest or when moving), as well as the frequency and intensity of trembling.
2. Muscle stiffness. Experts can test muscle stiffness by evaluating resistance during passive limb movement.
3. Slow motion. This can be verified by observing the patient's ability to perform simple movements (for example, head turns, arm and leg movements).
4. Problems with balance and coordination. Experts can check the balance by forcing the patient to stand on one leg or walk in a straight line, as well as evaluating the coordination of movements.
5. Speech. Patients with Parkinson's disease may have problems with clear and understandable speech, so specialists can evaluate their ability to speak and pronounce sounds.

Various scales and tests can be used to monitor signs of Parkinson's disease, such as the Parkinson's Disease Assessment Scale (UPDRS) and the Walking Test (TUG). These tools can help in assessing the severity of the disease and the progression of its symptoms.

In addition, monitoring of signs of Parkinson's disease may include the following methods:

1. Examination of the state of the brain. MRI and other brain imaging techniques can be used to determine the extent of brain damage and assess the progression of the disease.
2. Determination of dopamine levels. Measuring the level of dopamine in the brain can help in the diagnosis of Parkinson's disease, as well as in tracking its progression.
3. Monitoring of drug therapy. Medications such as levodopa can help manage the symptoms of Parkinson's disease. Monitoring of drug therapy may include evaluating the effectiveness of drugs, determining the optimal dose and monitoring side effects.
4. Assessment of the quality of life. Parkinson's disease can significantly affect the patient's quality of life. The quality of life assessment may include determining the level of life satisfaction, assessing the ability to perform everyday tasks, and determining the level of anxiety and depression.

In general, monitoring the signs of Parkinson's disease is an important component of disease management. Early diagnosis and constant monitoring will help in managing symptoms, improving the patient's quality of life and slowing the progression of the disease.[13]

Artificial intelligence (AI) plays an important role in the diagnosis of Parkinson's disease. Thanks to the use of various machine learning algorithms, AI can process and analyze large amounts of medical data and identify hidden patterns that can help in the diagnosis of Parkinson's disease.

Some of the methods using artificial intelligence in the diagnosis of Parkinson's disease include:

1. **Voice analysis:** Studies have shown that in patients with Parkinson's disease, the tone of voice and intonation change. Artificial intelligence can be used to analyze the voice and identify characteristic changes, which can help in the diagnosis of the disease.
2. **Gait analysis:** Patients with Parkinson's disease may have changes in gait. Artificial intelligence can be used to analyze gait videos and identify characteristic changes.
3. **Brain Image Analysis:** AI can be used to analyze brain images obtained by MRI and other methods to identify changes associated with Parkinson's disease.
4. **Mobile device data analysis:** Patients with Parkinson's disease can use mobile devices to track their symptoms and disease progression.[14]

Artificial intelligence can be used to analyze this data and identify characteristic changes that may indicate Parkinson's disease.

It should also be noted that the development of diagnostic capabilities for Parkinson's disease will not only help in the diagnosis of the disease itself, but can also play an important role in the development of new therapeutic approaches. For example, the use of biomarkers can help in identifying new molecular targets for drugs and improving their effectiveness.[15] In general, the development of diagnostic capabilities for Parkinson's disease is an important direction in medical research, which can lead to a more accurate and early diagnosis of the disease and improve the quality of life of patients.[16]

CONCLUSION

Modern medicine has a number of methods that help to detect Parkinson's disease in the early stages.

Some of these methods include clinical assessments, where a doctor may conduct a physical exam including an assessment of balance, coordination and trembling of the limbs to determine the presence of symptoms of Parkinson's disease; neuropsychological tests, when some tests may be conducted to assess psychological functions such as memory, concentration and reaction speed that may be affected by the disease Parkinson 's Disease; imaging, when magnetic resonance imaging (MRI) and positron emission tomography (PET) can be used to study the brain and identify changes associated with Parkinson's disease; genetic tests, when some genes associated with Parkinson's disease can be detected in the patient's blood, which can help doctors in diagnosis; biomarkers when studying biological markers, such as the level of alpha-synuclein protein in the cerebrospinal fluid, can help in the diagnosis of Parkinson's disease; monitoring when some portable devices can be used to monitor the patient's movements and identify changes that may be associated with Parkinson's disease.

Although there is no specific test that can unambiguously diagnose Parkinson's disease in the early stages, a combination of these methods can help doctors more accurately determine the presence of the disease. Early diagnosis can help patients start treatment and improve their prognosis. The use of artificial intelligence in the diagnosis of Parkinson's disease can help improve the accuracy of diagnosis, identify the disease at earlier stages and provide patients with more effective management of their symptoms.

CONFLICT OF INTEREST: The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS: All authors contributed in reviewing the final version of this paper

REFERENCES

1. Wright-Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. *Neuroepidemiology*. 2010;34(3):143–151.
2. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism – a prospective study. *Can J Neurol Sci*. 1991;18(3):275–278.
3. Ali K, Morris HR. Parkinson's disease: chameleons and mimics. *Pract Neurol*. 2015;15(1):14–25.
4. Pont-sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). *Mov Disord*. 2015;30(2):229–237.
5. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. *Neurology*. 2014;83(19):1739–1746.
6. Thenganatt MA, Jankovic J. Parkinson disease subtypes. *JAMA Neurol*. 2014;71(4):499–504.
7. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. *Mov Disord*. 2012;27(6):709–715. Ji, W., and Li, Y. (2012). Energy-based feature ranking for assessing the dysphonia measurements in Parkinson detection. *IET Signal Proc*. 6, 300–305
8. I, K., Ulukaya, S., and Erdem, O.. Classification of Parkinson's disease using dynamic time warping, in *2019 27th Telecommunications Forum (TELFOR)* (Belgrade), 2019,1–4
9. Haller, S., Badoud, S., Nguyen, D., Garibotto, V., Lovblad, K. O., and Burkhard, P. R. Individual detection of patients with Parkinson disease using support vector machine analysis of diffusion tensor imaging data: initial results. *Am. J. Neuroradiol, 2012* 33, 2123–2128
10. Ghassemi, N. H., Marxreiter, F., Pasluosta, C. F., Kugler, P., Schlachetzki, J., Schramm, A., et al.. Combined accelerometer and EMG analysis to differentiate essential tremor from Parkinson's disease. *Annu. Int. Conf. IEEE Eng. Med. Biol. Soc.* 2016, 672–675
11. Fernandes, C., Fonseca, L., Ferreira, F., Gago, M., Costa, L., Sousa, N., et al. Artificial neural networks classification of patients with Parkinsonism based on gait, in *2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)* (Madrid), 2018, 2024–2030.
12. Drotár, P., Mekyska, J., Rektorová, I., Masarová, L., Smékal, Z., and Faundez-Zanuy, M.. Evaluation of handwriting kinematics and pressure for differential diagnosis of Parkinson's disease. *Artif. Intell. Med.* 2016, 67, 39–46
13. Dorsey, E. R., Elbaz, A., Nichols, E., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol, 2018,* 17, 939–953.
14. Dhami, D. S., Soni, A., Page, D., and Natarajan, S. Identifying Parkinson's patients: a functional gradient boosting approach. *Artif. Intell. Med. Conf. Artif. Intell. Med, 2017,* 10259, 332–337
15. Cook, D. J., Schmitter-Edgecombe, M., and Dawadi, P. Analyzing activity behavior and movement in a naturalistic environment using smart home techniques. *IEEE J. Biomed. Health Inf., 2015,* 19, 1882–1892.